Publications

Click here to see a complete list of Dr. Kanthi's publications.

Publications

2020:

COVID-related publications:

1. Prothrombotic antiphospholipid antibodies in COVID-19 Zuo Y, Estes SK, Gandhi AA, Yalavarthi S, Ali RA, Shi H, Sule G, Gockman S, Madison JA, Zuo M, Woodard W, Lezak SP, Lugogo NL, Kanthi Y*, Knight JS*. (*co-corresponding) Science Translational Medicine. 2020 Nov 2:eabd3876. doi: 10.1126/scitranslmed.abd3876. PMID: 33139519
*selected for cover;
*highlighted by NIH Director Dr. Francis Collins in his weekly blog;
*featured in Time magazine

2. Neutrophil extracellular traps and thrombosis in COVID-19. Zuo Y, Zuo M, Yalavarthi S, Gockman K, Madison JA, Shi H, Woodard W, Lezak SP, Lugogo NL, Knight JS*, Kanthi Y.* (co-corresponding) J Thromb Thrombolysis. 2020 Nov 5:1-8. doi: 10.1007/s11239-020-02324-z. PMID: 33151461

3. Neutrophil calprotectin identifies severe pulmonary disease in COVID-19. Shi H, Zuo Y, Yalavarthi S, Gockman K, Zuo M, Madison JA, Blair C, Woodward W, Lezak SP, Lugogo NL, Woods RJ, Lood C, Knight JS, Kanthi Y. J Leukoc Biol. 2020 Sep 1. doi: 10.1002/JLB.3COVCRA0720-359R. PMID: 32869342

4. COVID-19 coagulopathy: an exploration of mechanisms. Colling ME and Kanthi Y. Vascular Medicine 2020 PMID: 32558620

5. New (re)Purpose for an old drug: purinergic receptor blockade may extinguish the COVID-19 thromboinflammatory firestorm. Kanthi Y*, Knight JS*, Zuo Y, Pinsky DJ*. JCI Insight 2020 PMID: 32530438
*featured in Medscape

6. Neutrophil extracellular traps in COVID-19. Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, Blair CN, Weber A, Barnes BJ, Egeblad M, Woods RJ, Kanthi Y*, Knight JS*. (*co-corresponding) JCI Insight 2020; PMID: 32329756
*selected for cover feature
*featured in Scientific American
*featured in The Scientist

Non-COVID publications:

7. Shining a light on venous thromboembolism. Kanthi Y* and Sharma AS. JACC Basic & Translational Science 2020 April;4(4). DOI: 10.1016/j.jacbts.2020.03.004

8. Nanotherapeutic shots through the heart of plaque. Kanthi Y and Smith BR. ACS Nano 2020; PMID: 31986012

9. Diagnostic approach and management of genetic aortopathies. Bhandari R, Aatre RD, and Kanthi Y*. Vascular Medicine . 2020 Feb;25(1):63-77 PMID: 32000633


Preprints:

  1. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Zuo Y, Warnock M, Harbaugh A, Yalavarthi S, Gockman K, Zuo M, Madison JA, Knight JS, Kanthi Y, Lawrence DA. medRxiv. 2020 Sep 2:2020.08.29.20184358. doi: 10.1101/2020.08.29.20184358. Preprint. PMID: 32909005

2019:

1. Ectonucleotidase tri(di)phosphohydrolase-1 (ENTPD-1) disrupts inflammasome/interleukin 1β-driven venous thrombosis. Yadav V, Chi L, Zhao R, Tourdot BE, Yalavarthi Y, Jacobs BN, Banka AL, Liao H, Koonse S, Anyanwu AC, Visovatti SH, Holinstat M, Kahlenberg JM, Knight JS, Pinsky DJ, Kanthi Y* J. Clinical Invest. 2019;39(4)e:118-129. *selected for cover image

2. Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome. Ali RA, Gandhi AA, Meng H, Yalavarthi S, Vreede AP, Estes S, Palmer OR, Bockenstedt PL, Pinsky DJ, Greve JM, Diaz JA, Kanthi Y, Knight JS. Nat Communications. 2019; 10:1916.

3. Tuning the thromboinflammatory response to venous flow interruption by the ectonucleotidase CD39. Anyanwu AC, Kanthi Y*, Fukase K, Liao H, Mimura T, Desch KC, Gruca M, Kaskar S, Sheikh-Aden H, Chi L, Zhao R, Yadav V, Wakefield TW, Hyman MC, Pinsky DJ*. ATVB. 2019; 39(4):e112-e119 PMID: 30816804 (*corresponding)

4. Genetic aortopathies: Diagnostic approach and management. Bhandari R, Aatre RD, Kanthi Y* Vasc Med Journal. 2019; 25(1):63-77

2018:

1. Ectonucleotidase-Mediated Suppression of Lupus Autoimmunity and Vascular Dysfunction. Knight JS, Mazza LF, Yalavarthi S, Sule G, Ali RA, Hodgin JB, Kanthi Y, Pinsky DJ. Front Immunol. 2018 Jun 11;9:1322. PMID: 29942314

2. Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics. Tourdot BE, Stoveken H, Trumbo D, Yeung J, Kanthi Y, Edelstein LC, Bray PF, Tall GG, Holinstat M. Arterioscler Thromb Vasc Biol. 2018 Jul;38(7):1632-1643. PMID: 29748334

3. Great Debates in Vascular Medicine: Extended duration anticoagulation for unprovoked venous thromboembolism - Coming to consensus when the debate rages on. Kanthi Y*, Piazza G. Vasc Med. 2018 Aug;23(4):384-387. PMID: 29734862

4. Images in Vascular Medicine: Distal radial and ulnar artery thrombosis in a cancer patient with a history of chronic handgun use. Hage AN, Eliason JL, Kanthi Y. Vasc Med. 2018 Feb;23(1):84-85. Epub 2017 Nov 22. PMID: 29165047


2017:

1. Ischemic Cerebroprotection Conferred by Myeloid Lineage-Restricted or Global CD39 Transgene Expression. Baek AE, Sutton NR, Petrovic-Djergovic D, Liao H, Ray JJ, Park J, Kanthi Y, Pinsky DJ. Circulation. 2017 Jun 13;135(24):2389-2402. Apr 4. PMID: 28377485

2. Ectonucleotidase CD39-driven control of postinfarction myocardial repair and rupture. Sutton NR, Hayasaki T, Hyman MC, Anyanwu AC, Liao H, Petrovic-Djergovic D, Badri L, Baek AE, Walker N, Fukase K, Kanthi Y, Visovatti SH, Horste EL, Ray JJ, Goonewardena SN, Pinsky DJ. JCI Insight. 2017 Jan 12;2(1):e89504. PMID: 28097233

3. In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis. Meng H, Yalavarthi S, Kanthi Y, Mazza LF, Elfline MA, Luke CE, Pinsky DJ, Henke PK, Knight JS. Arthritis Rheumatol. 2017 Mar;69(3):655-667. PMID: 27696751

4. Nanoparticle-macrophage interactions: A balance between clearance and cell-specific targeting. Rattan R, Bhattacharjee S, Zong H, Swain C, Siddiqui MA, Visovatti SH, Kanthi Y, Desai S, Pinsky DJ, Goonewardena SN. Bioorg Med Chem. 2017 Aug 15;25(16):4487-4496. PMID: 28705434

5. Ruptured external jugular varix. Kindzelski BA, Chen H, Kanthi Y, Wakefield T, Coleman DM. J Vasc Surg Venous Lymphat Disord. 2017 Jan;5(1):121-123. PMID: 27987600


2016:

1. Endotoxaemia-augmented murine venous thrombosis is dependent on TLR-4 and ICAM-1, and potentiated by neutropenia. Obi AT, Andraska E, Kanthi Y, Kessinger CW, Elfline M, Luke C, Siahaan TJ, Jaffer FA, Wakefield TW, Henke PK. Thromb Haemost. 2017 Jan 26;117(2):339-348. doi: 10.1160/TH16-03-0218. Epub 2016 Dec 15. PMID: 27975098

2. Gram-Negative Pneumonia Alters Large-Vein Cell-Adhesion Molecule Profile and Potentiates Experimental Stasis Venous Thrombosis. Obi AT, Andraska E, Kanthi Y, Luke CE, Elfline M, Madathilparambil S, Siahaan TJ, Jaffer FA, Wakefield TW, Raghavendran K, Henke PK. J Vasc Res. 2016;53(3-4):186-195. PMID: 27771726

3. Purinergic dysregulation in pulmonary hypertension. Visovatti SH, Hyman MC, Goonewardena SN, Anyanwu AC, Kanthi Y, Robichaud P, Wang J, Petrovic-Djergovic D, Rattan R, Burant CF, Pinsky DJ. Am J Physiol Heart Circ Physiol. 2016 Jul 1;311(1):H286-98. PMID: 27208163


2015:

1. Flow-dependent expression of ectonucleotide tri(di)phosphohydrolase-1 and suppression of atherosclerosis. Kanthi Y*, Hyman MC*, Liao H, Baek AE, Visovatti SH, Sutton NR, Goonewardena SN, Neral MK, Jo H, Pinsky DJ. J Clin Invest. 2015 Aug 3;125(8):3027-36. PMID: 26121751

2. Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation. Barnes GD, Kanthi Y, Froehlich JB. Vasc Med. 2015 Apr;20(2):143-52. PMID: 25832602


2014:

1. CD39: Interface between vascular thrombosis and inflammation. Kanthi Y, Sutton NR, Pinsky DJ. Curr Atheroscler Rep. 2014 Jul;16(7):425. PMID:24838375


2013:

1. Regulation of ecto-apyrase CD39 (ENTPD1) expression by phosphodiesterase III (PDE3). Baek AE, Kanthi Y, Sutton NR, Liao H, Pinsky DJ. FASEB J. 2013 Nov;27(11):4419-28. PMID: 23901069